Cargando…
Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania
BACKGROUND: Sulfadoxine–pyrimethamine (SP) is recommended for prophylactic treatment of malaria in pregnancy while artemisinin combination therapy is the recommended first-line anti-malarial treatment. Selection of SP resistance is ongoing since SP is readily available in health facilities and in pr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918075/ https://www.ncbi.nlm.nih.gov/pubmed/27339129 http://dx.doi.org/10.1186/s12936-016-1387-2 |
_version_ | 1782439054197915648 |
---|---|
author | Kavishe, Reginald A. Kaaya, Robert D. Nag, Sidsel Krogsgaard, Camilla Notland, Jakob Ginsbak Kavishe, Adellaida A. Ishengoma, Deus Roper, Cally Alifrangis, Michael |
author_facet | Kavishe, Reginald A. Kaaya, Robert D. Nag, Sidsel Krogsgaard, Camilla Notland, Jakob Ginsbak Kavishe, Adellaida A. Ishengoma, Deus Roper, Cally Alifrangis, Michael |
author_sort | Kavishe, Reginald A. |
collection | PubMed |
description | BACKGROUND: Sulfadoxine–pyrimethamine (SP) is recommended for prophylactic treatment of malaria in pregnancy while artemisinin combination therapy is the recommended first-line anti-malarial treatment. Selection of SP resistance is ongoing since SP is readily available in health facilities and in private drug shops in sub-Saharan Africa. This study reports on the prevalence and distribution of Pfdhps mutations A540E and A581G in Tanzania. When found together, these mutations confer high-level SP resistance (sometimes referred to as ‘super-resistance’), which is associated with loss in protective efficacy of SP-IPTp. METHODS: DNA samples were extracted from malaria-positive blood samples on filter paper, used malaria rapid diagnostic test strips and whole blood collected from eight sites in seven administrative regions of Tanzania. PCR–RFLP and SSOP-ELISA techniques were used to genotype the A540E and A581G Pfdhps. Data were analysed using SPSS version 18 while Chi square and/or Fischer Exact tests were used to compare prevalence between regions. RESULTS: A high inter-regional variation of Pfdhps-540E was observed (χ(2) = 76.8, p < 0.001). High inter-regional variation of 581G was observed (FE = 85.3, p < 0.001). Both Tanga and Kagera were found to have the highest levels of SP resistance. A high prevalence of Pfdhps-581G was observed in Tanga (56.6 %) in northeastern Tanzania and in Kagera (20.4 %) in northwestern Tanzania and the 540–581 EG haplotype was found at 54.5 and 19.4 %, respectively. Pfdhps-581G was not detected in Pwani and Lindi regions located south of Tanga region. CONCLUSIONS: Selection of SP super-resistant Pfdhps A581G is highest in northern Tanzania. Variation in distribution of SP resistance is observed across the country: northeastern Tanga region and northwestern Kagera region have highest prevalence of SP super-resistance markers, while in Pwani and Lindi in the southeast the prevalence of super-resistance was zero. More studies should be conducted to understand the factors underlying the remarkable heterogeneity in SP resistance in the country. |
format | Online Article Text |
id | pubmed-4918075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49180752016-06-24 Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania Kavishe, Reginald A. Kaaya, Robert D. Nag, Sidsel Krogsgaard, Camilla Notland, Jakob Ginsbak Kavishe, Adellaida A. Ishengoma, Deus Roper, Cally Alifrangis, Michael Malar J Research BACKGROUND: Sulfadoxine–pyrimethamine (SP) is recommended for prophylactic treatment of malaria in pregnancy while artemisinin combination therapy is the recommended first-line anti-malarial treatment. Selection of SP resistance is ongoing since SP is readily available in health facilities and in private drug shops in sub-Saharan Africa. This study reports on the prevalence and distribution of Pfdhps mutations A540E and A581G in Tanzania. When found together, these mutations confer high-level SP resistance (sometimes referred to as ‘super-resistance’), which is associated with loss in protective efficacy of SP-IPTp. METHODS: DNA samples were extracted from malaria-positive blood samples on filter paper, used malaria rapid diagnostic test strips and whole blood collected from eight sites in seven administrative regions of Tanzania. PCR–RFLP and SSOP-ELISA techniques were used to genotype the A540E and A581G Pfdhps. Data were analysed using SPSS version 18 while Chi square and/or Fischer Exact tests were used to compare prevalence between regions. RESULTS: A high inter-regional variation of Pfdhps-540E was observed (χ(2) = 76.8, p < 0.001). High inter-regional variation of 581G was observed (FE = 85.3, p < 0.001). Both Tanga and Kagera were found to have the highest levels of SP resistance. A high prevalence of Pfdhps-581G was observed in Tanga (56.6 %) in northeastern Tanzania and in Kagera (20.4 %) in northwestern Tanzania and the 540–581 EG haplotype was found at 54.5 and 19.4 %, respectively. Pfdhps-581G was not detected in Pwani and Lindi regions located south of Tanga region. CONCLUSIONS: Selection of SP super-resistant Pfdhps A581G is highest in northern Tanzania. Variation in distribution of SP resistance is observed across the country: northeastern Tanga region and northwestern Kagera region have highest prevalence of SP super-resistance markers, while in Pwani and Lindi in the southeast the prevalence of super-resistance was zero. More studies should be conducted to understand the factors underlying the remarkable heterogeneity in SP resistance in the country. BioMed Central 2016-06-23 /pmc/articles/PMC4918075/ /pubmed/27339129 http://dx.doi.org/10.1186/s12936-016-1387-2 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Kavishe, Reginald A. Kaaya, Robert D. Nag, Sidsel Krogsgaard, Camilla Notland, Jakob Ginsbak Kavishe, Adellaida A. Ishengoma, Deus Roper, Cally Alifrangis, Michael Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania |
title | Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania |
title_full | Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania |
title_fullStr | Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania |
title_full_unstemmed | Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania |
title_short | Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in Tanzania |
title_sort | molecular monitoring of plasmodium falciparum super-resistance to sulfadoxine–pyrimethamine in tanzania |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918075/ https://www.ncbi.nlm.nih.gov/pubmed/27339129 http://dx.doi.org/10.1186/s12936-016-1387-2 |
work_keys_str_mv | AT kavishereginalda molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT kaayarobertd molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT nagsidsel molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT krogsgaardcamilla molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT notlandjakobginsbak molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT kavisheadellaidaa molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT ishengomadeus molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT ropercally molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania AT alifrangismichael molecularmonitoringofplasmodiumfalciparumsuperresistancetosulfadoxinepyrimethamineintanzania |